BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7855620)

  • 1. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
    Stadler WM; Vogelzang NJ
    Semin Oncol; 1995 Feb; 22(1):67-73. PubMed ID: 7855621
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
    Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW; Fuchs HA
    J Rheumatol; 1994 Apr; 21(4):752-3. PubMed ID: 8035405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
    [No Abstract]   [Full Text] [Related]  

  • 12. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K; Tazaki H
    Prog Clin Biol Res; 1990; 350():263-73. PubMed ID: 2117286
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cell therapy in renal cell carcinoma].
    Ravaud A
    Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell carcinoma: current status and future plans.
    Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S52-4. PubMed ID: 10685659
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin 2 and psoriasis.
    Lee RE; Gaspari AA; Lotze MT; Chang AE; Rosenberg SA
    Arch Dermatol; 1988 Dec; 124(12):1811-5. PubMed ID: 3263840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.